The emerging implications of GLP-1 receptor agonists in radiation therapy.

Authors

• Trenton Reinicke, Oakland University William Beaumont School of Medicine Medical Student
• Joshua T. Dilworth, Corewell Health East

Document Type

Article

Publication Date

3-9-2026

Publication Title

The oncologist

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for patients with diabetes, obesity, and cardiometabolic disease. This trend has led to a growing number of patients taking these medications while receiving cancer treatment, including radiation therapy (RT). The delivery of RT relies on weight stability and anatomic reproducibility, which may be influenced by GLP-1 RA-related weight loss, delayed gastric emptying, and associated side effects. While current research has largely focused on perioperative outcomes and metabolic effects, we discuss the impact that GLP-1 RA use may have on radiation treatment planning, the need for adaptive radiation techniques, and RT related toxicity. We propose strategies to support safe RT and highlight the need for consensus recommendations regarding the use of GLP-1 RAs in patients requiring cancer treatment.

Volume

31

Issue

4

First Page

oyag07

Recommended Citation

Reinicke T, Dilworth JT. The emerging implications of GLP-1 receptor agonists in radiation therapy. Oncologist. 2026 Mar 9;31(4):oyag073. doi: 10.1093/oncolo/oyag073. PMID: 41776829

DOI

10.1093/oncolo/oyag073

ISSN

1549-490X

PubMed ID

41776829